Extracorporeal membrane oxygenation for acute respiratory distress syndrome due to Pneumocystis pneumonia. Issue 3 (19th September 2019)
- Record Type:
- Journal Article
- Title:
- Extracorporeal membrane oxygenation for acute respiratory distress syndrome due to Pneumocystis pneumonia. Issue 3 (19th September 2019)
- Main Title:
- Extracorporeal membrane oxygenation for acute respiratory distress syndrome due to Pneumocystis pneumonia
- Authors:
- Stahl, Klaus
Schenk, Heiko
Seeliger, Benjamin
Wiesner, Olaf
Schmidt, Julius J.
Bauersachs, Johann
Welte, Tobias
Kühn, Christian
Haverich, Axel
Hoeper, Marius M.
David, Sascha - Abstract:
- Pneumocystis jirovecii pneumonia (PcP) occurs exclusively in immunocompromised patients. About 50% of PcP is HIV related, the other half is associated with immunosuppression for other reasons [1]. If PcP progresses to an acute respiratory distress syndrome (ARDS) requiring intensive care and invasive mechanical ventilation, the prognosis is generally poor [1] and mortality is about 80% if additional veno-venous extracorporeal membrane oxygenation (VV-ECMO) support is necessary [1]. Despite lack of clear evidence [2], VV-ECMO has become an integral part in the rescue therapy of severe ARDS. Moreover, some centres start VV-ECMO at early time-points in order to rigorously follow (ultra-) protective ventilation strategies [3]. So far, VV-ECMO in patients with PcP-associated ARDS has been reported only on the basis of singular case reports, including one case of awake ECMO [4]. Using ECMO in patients who are awake and spontaneously breathing might avoid complications associated with sedation and invasive mechanical ventilation. Our group was the first to describe this awake ECMO approach in a bridge-to-transplant setting [5, 6] as well as in a small number of ARDS patients [7, 8]. However, evidence on the safety and efficacy of awake VV-ECMO strategies in this population is lacking [7]. PcP classically leads to an isolated single organ failure without accompanying systemic complications such as septic shock with haemodynamic instability or acute kidney injury (AKI). At the samePneumocystis jirovecii pneumonia (PcP) occurs exclusively in immunocompromised patients. About 50% of PcP is HIV related, the other half is associated with immunosuppression for other reasons [1]. If PcP progresses to an acute respiratory distress syndrome (ARDS) requiring intensive care and invasive mechanical ventilation, the prognosis is generally poor [1] and mortality is about 80% if additional veno-venous extracorporeal membrane oxygenation (VV-ECMO) support is necessary [1]. Despite lack of clear evidence [2], VV-ECMO has become an integral part in the rescue therapy of severe ARDS. Moreover, some centres start VV-ECMO at early time-points in order to rigorously follow (ultra-) protective ventilation strategies [3]. So far, VV-ECMO in patients with PcP-associated ARDS has been reported only on the basis of singular case reports, including one case of awake ECMO [4]. Using ECMO in patients who are awake and spontaneously breathing might avoid complications associated with sedation and invasive mechanical ventilation. Our group was the first to describe this awake ECMO approach in a bridge-to-transplant setting [5, 6] as well as in a small number of ARDS patients [7, 8]. However, evidence on the safety and efficacy of awake VV-ECMO strategies in this population is lacking [7]. PcP classically leads to an isolated single organ failure without accompanying systemic complications such as septic shock with haemodynamic instability or acute kidney injury (AKI). At the same time, these patients often require prolonged invasive mechanical ventilation with a high risk of complications including ventilator-associated pneumonia and pneumothorax. Hence, patients with PcP and severe hypoxaemia may be candidates for an awake ECMO strategy as a bridge to recovery. Extracorporeal membrane oxygenation (ECMO) may be justified in immunocompromised patients with Pneumocystis -associated acute respiratory distress syndrome, and an awake ECMO strategy might be feasible in selected patients http://bit.ly/2YFyrOK … (more)
- Is Part Of:
- European respiratory journal. Volume 54:Issue 3(2019)
- Journal:
- European respiratory journal
- Issue:
- Volume 54:Issue 3(2019)
- Issue Display:
- Volume 54, Issue 3 (2019)
- Year:
- 2019
- Volume:
- 54
- Issue:
- 3
- Issue Sort Value:
- 2019-0054-0003-0000
- Page Start:
- Page End:
- Publication Date:
- 2019-09-19
- Subjects:
- Respiratory organs -- Diseases -- Periodicals
Respiration -- Periodicals
616.2 - Journal URLs:
- http://erj.ersjournals.com ↗
http://www.ersnet.org ↗
http://www.blackwell-synergy.com/member/institutions/issuelist.asp?journal=mrj ↗
http://www.ingenta.com/journals/browse/ers/erj?mode=direct ↗ - DOI:
- 10.1183/13993003.00410-2019 ↗
- Languages:
- English
- ISSNs:
- 0903-1936
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24807.xml